Business Wire

TX-SNOW-SOFTWARE

17.11.2022 15:01:53 CET | Business Wire | Press release

Share
IT Leaders May Underestimate the Risk of Shadow SaaS, Finds New Snow Software Survey

Snow Software, the global leader in technology intelligence, today unveiled new data highlighting the challenges facing IT leaders due to expanded software as a service (SaaS) usage. While a huge majority of IT leaders (96%) indicated they were ‘confident or very confident’ in their organization’s SaaS security measures, the top challenge for leaders managing SaaS was ‘employees adding new SaaS applications without notifying IT,’ suggesting that leaders may underestimate the importance of visibility in security.

According to IDC, SaaS is the top source for cloud spend in 2022, accounting for $177.8 billion of the market. In the new Snow survey examining the state of SaaS management, which surveyed 1,000 IT leaders from large organizations of 500+ employees in the United States and United Kingdom, 44% said ‘employees adding new SaaS applications without notifying IT’ is their top challenge to managing SaaS applications at their organization, closely followed by managing SaaS security (42%). When asked why these issues were so challenging, IT leaders indicated the impact to other IT programs (47%), organizational dynamics (38%), lack of time and resources (37%) and lack of visibility (36%).

“Post-pandemic IT teams are seeing a large increase in SaaS applications procured without the knowledge of IT,” said Becky Trevino, Executive Vice President of Products at Snow. “Amid increasing cybersecurity risks and mounting pressure to cut costs, IT leaders realize they need to better govern unknown and unsanctioned SaaS usage. CIOs are ultimately responsible for the security and management of SaaS applications regardless of where they are procured, and to do this effectively IT needs complete visibility into what it is they need to secure.”

Views on budget and security ownership depends on your leadership level

Cybersecurity is a major focus for IT decision-makers right now, particularly as business leaders navigate market uncertainty and plan 2023 budgets in anticipation of a recession. However, ownership is not clear among IT leaders, which can put organizations at risk for elevated costs and gaps in security.

  • IT leaders ranked ‘managing the security of SaaS applications’ as the #1 most important issue to managing SaaS applications at their organization, followed by ‘identifying usage of all SaaS applications within our organization.’
  • Ninety-six percent of those surveyed reported feeling ‘confident’ or ‘very confident’ in their organization’s SaaS security measures.
  • According to the survey, SaaS purchasing power and IT/security responsibility rests firmly within two groups: CIOs/IT leadership and IT asset management (ITAM) or software asset management (SAM) teams.
  • Senior leaders (41% of vice presidents, 45% of sr. vice presidents and 52% of C-level executives) look to the CIO and/or IT leadership to take responsibility for SaaS purchasing and security issues over other departments and roles, while more mid-level management (50% of managers and 44% of directors) put the onus of SaaS management and security on peers within ITAM/SAM.
  • Forty-eight percent of IT leaders surveyed said that if budget, resources and time were not a factor, they’d like to pivot all SaaS application spending to IT to address SaaS sprawl.

Economic uncertainty is elevating cost concerns among IT leaders – though it’s not the top priority

Market conditions are driving increased scrutiny across all areas of cost in most organizations and optimizing spend while eliminating waste is an ongoing priority for IT teams. However, of those surveyed, IT leaders are currently more focused on cybersecurity of SaaS applications than costs.

  • Despite continued uncertainty across the global markets, reining in the total cost of SaaS applications was ranked 5th on respondents’ priorities.
  • If global uncertainty persists, more than three quarters of all respondents (77%) believe IT spend will decrease by as much as 50% to 75%.
  • If IT spending decreases, IT leaders believe that the two core areas impacted will be IT staffing (20%) and strategic IT initiatives or programs (19%).

For more information about Snow’s latest survey, please visit: https://www.snowsoftware.com/blog/survey-anxiety-over-saas-security-plagues-it-leaders/

About Snow Software

Snow Software is changing the way organizations understand and manage their technology consumption. Our technology intelligence platform provides comprehensive visibility and contextual insight across software, SaaS, hardware and cloud. With Snow, IT leaders can effectively optimize resources, enhance performance and enable operational agility in a hybrid world. To learn more, visit www.snowsoftware.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005232/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye